Harrow Health (HROW) Price & Analysis

Q: How many shares outstanding does Harrow Health Inc have?

Harrow Health Inc has 36,699,554 shares outstanding.

Q: What happened to Harrow Health Inc’s price movement after its last earnings report?

Harrow Health Inc reported an EPS of -$0.5 in its last earnings report, missing expectations of -$0.046. Following the earnings report the stock price went up 3.434%.

Compare

378 Followers

HROW Stock Chart & Stats

Day’s Range― - ―

52-Week Range$20.85 - $59.23

Previous CloseN/A

Volume51.77K

Average Volume (3M)391.76K

Market Cap

$1.26B

Enterprise Value$1.42B

Total Cash (Recent Filing)$66.73M

Total Debt (Recent Filing)$230.01M

Price to Earnings (P/E)―

Beta1.78

Next Earnings

Aug 12, 2025

EPS Estimate

<0.01

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.50

Shares Outstanding36,699,554

10 Day Avg. Volume414,255

30 Day Avg. Volume391,758

Financial Highlights & Ratios

PEG Ratio2.30

Price to Book (P/B)21.68

Price to Sales (P/S)0.00

P/FCF Ratio-34.24

Enterprise Value/Market Cap1.13

Enterprise Value/Revenue1.94

Enterprise Value/Gross Profit8.98

Enterprise Value/Ebitda34.08

Forecast

1Y Price Target

$60.00

Price Target Upside66.02% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering6

Harrow Health News

See All News >

Bulls Say, Bears Say

Bulls Say

Acquisition And PartnershipsHarrow announced an agreement with Samsung Bioepis to acquire exclusive U.S. commercial rights to Byooviz and Opuviz, biosimilars for Lucentis and Eylea, respectively.

Product Adoption And Market ExpansionThe company's product Vevye has had good adoption and impressive refill rates, supporting a long and durable growth profile in the market for dry eye disease.

Revenue GrowthManagement reiterated 2025 revenue target of over $280M, which would represent a growth rate of over 40% in 2025.

Bears Say

Earnings Results1Q25 results were somewhat disappointing, although partly based on standard seasonal effects, which may have created an attractive entry point for the stock.

Financial PerformanceNet loss was $17.8M, or ($0.50) per share, missing estimated income of $1.5M.

Product Launch DelaysWhile approved by the FDA, Opuviz has not yet launched and is not expected to launch until the expiration of Eylea’s IP in mid-2027.

Financials

Income Statement >

Options Prices

Detailed Option Prices >

Ownership Overview

25.99% Insiders

10.13% Mutual Funds

24.26% Other Institutional Investors

28.92% Public Companies and Individual Investors

Detailed Ownership Overview >

HROW FAQ

What was Harrow Health Inc’s price range in the past 12 months?

Harrow Health Inc lowest stock price was $20.85 and its highest was $59.23 in the past 12 months.

What is Harrow Health Inc’s market cap?

Harrow Health Inc’s market cap is $1.26B.

When is Harrow Health Inc’s upcoming earnings report date?

Harrow Health Inc’s upcoming earnings report date is Aug 12, 2025 which is in 25 days.

How were Harrow Health Inc’s earnings last quarter?

Harrow Health Inc released its earnings results on May 08, 2025. The company reported -$0.5 earnings per share for the quarter, missing the consensus estimate of -$0.046 by -$0.454.

Is Harrow Health Inc overvalued?

According to Wall Street analysts Harrow Health Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Harrow Health Inc pay dividends?

Harrow Health Inc does not currently pay dividends.

What is Harrow Health Inc’s EPS estimate?

Harrow Health Inc’s EPS estimate is <0.01.

How many shares outstanding does Harrow Health Inc have?

Harrow Health Inc has 36,699,554 shares outstanding.

What happened to Harrow Health Inc’s price movement after its last earnings report?

Harrow Health Inc reported an EPS of -$0.5 in its last earnings report, missing expectations of -$0.046. Following the earnings report the stock price went up 3.434%.

Which hedge fund is a major shareholder of Harrow Health Inc?

Currently, no hedge funds are holding shares in HROW

Harrow Health Stock Smart Score

Outperform

Fundamentals

Return on Equity

-37.23%

Trailing 12-Months

Asset Growth

23.42%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Harrow Health Inc

Harrow Health, Inc. (HROW) is a pharmaceutical company primarily focused on the development, production, and commercialization of innovative medications, especially in the ophthalmic sector. The company is dedicated to providing specialty pharmaceutical products and services to eyecare professionals, enhancing patient care through its proprietary compounding formulations and FDA-approved products.

HROW Company Deck

HROW Earnings Call

Q1 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

Harrow demonstrated strong revenue growth and cash flow, along with successful strategic initiatives in product launches and market access. However, the quarter was marred by seasonal revenue weakness and significant one-time expenses. The company's outlook remains positive with expectations for growth in the remainder of the year.Read More>

HROW Stock 12 Month Forecast

Average Price Target

$60.00

▲(66.02%Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"20":"$20","77":"$77","34.25":"$34.3","48.5":"$48.5","62.75":"$62.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":76,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$76.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":60,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$60.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":42,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$42.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[20,34.25,48.5,62.75,77],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,30.77,34.24923076923077,37.72846153846154,41.20769230769231,44.68692307692308,48.16615384615385,51.645384615384614,55.12461538461538,58.603846153846156,62.08307692307693,65.5623076923077,69.04153846153847,72.52076923076923,{"y":76,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,30.77,33.01846153846154,35.26692307692308,37.51538461538461,39.76384615384615,42.01230769230769,44.26076923076923,46.50923076923077,48.75769230769231,51.00615384615384,53.25461538461538,55.50307692307692,57.75153846153846,{"y":60,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,30.77,31.633846153846154,32.497692307692304,33.36153846153846,34.22538461538461,35.08923076923077,35.95307692307692,36.816923076923075,37.68076923076923,38.54461538461538,39.40846153846154,40.27230769230769,41.136153846153846,{"y":42,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":21.05,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.55,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.46,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.45,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.64,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.86,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.55,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.72,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.08,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.98,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.98,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.77,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >